1. Spaide RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996; 103:2070–2079.
2. Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999; 128:63–68.
3. Yannuzzi LA. Type-A behavior and central serous chorioretinopathy. Retina. 1987; 7:111–131.
4. Tsai DC, Chen SJ, Huang CC, et al. Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001–2006: a population-based study. PLoS One. 2013; 8:e66858.
5. Conrad R, Geiser F, Kleiman A, et al. Temperament and character personality profile and illness-related stress in central serous chorioretinopathy. ScientificWorldJournal. 2014; 2014:631687.
6. Piskunowicz M, Jaracz M, Lesiewska H, et al. Temperament profile in patients with central serous chorioretinopathy: a case-control study. Eur J Ophthalmol. 2014; 24:392–395.
7. Sahin A, Bez Y, Kaya MC, et al. Psychological distress and poor quality of life in patients with central serous chorioretinopathy. Semin Ophthalmol. 2014; 29:73–76.
8. Bazzazi N, Ahmadpanah M, Akbarzadeh S, et al. In patients suffering from idiopathic central serous chorioretinopathy, anxiety scores are higher than in healthy controls, but do not vary according to sex or repeated central serous chorioretinopathy. Neuropsychiatr Dis Treat. 2015; 11:1131–1136.
9. Caccavale A, Romanazzi F, Imparato M, et al. Central serous chorioretinopathy: a pathogenetic model. Clin Ophthalmol. 2011; 5:239–243.
10. Conrad R, Bodeewes I, Schilling G, et al. Central serous chorioretinopathy and psychological stress. Ophthalmologe. 2000; 97:527–531.
11. Conrad R, Weber NF, Lehnert M, et al. Alexithymia and emotional distress in patients with central serous chorioretinopathy. Psychosomatics. 2007; 48:489–495.
12. Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina. 1994; 14:231–242.
13. Spaide RF, Hall L, Haas A, et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina. 1996; 16:203–213.
14. Spielberger CD, Gorsuch RL, Lushene R, et al. Manual for the State-Trait Anxiety Inventory. Palo Alto: Consulting Psychologists Press;1983.
15. Hahn DW, Lee CH, Chon KK. Korean adaptation of Spielberger's STAI (K-STAI). Korean J Health Psychol. 1996; 1:1–14.
16. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561–571.
17. Holmes TH, Rahe RH. The social readjustment rating scale. J Psychosom Res. 1967; 11:213–218.
18. Endler NS, Parker JD. Multidimensional assessment of coping: a critical evaluation. J Pers Soc Psychol. 1990; 58:844–854.
19. Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991; 32:705–714.
20. Spahn C, Wiek J, Burger T, Hansen L. Psychosomatic aspects in patients with central serous chorioretinopathy. Br J Ophthalmol. 2003; 87:704–708.
21. Franke GH, Esser J, Stacker KH, et al. “Filtered normality”: psychological causes and sequelae of specific retinal diseases. Psychother Psychosom Med Psychol. 1996; 46:159–168.
22. Lahousen T, Painold A, Luxenberger W, et al. Psychological factors associated with acute and chronic central serous chorioretinopathy. Nord J Psychiatry. 2016; 70:24–30.
23. Zhao M, Celerier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012; 122:2672–2679.
24. Daruich A, Matet A, Dirani A, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015; 48:82–118.
25. Bousquet E, Beydoun T, Rothschild PR, et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina. 2015; 35:2505–2515.
26. Daruich A, Matet A, Dirani A, et al. Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl Vis Sci Technol. 2016; 5:2.
27. Ghadiali Q, Jung JJ, Yu S, et al. Central serous chorioretinopathy treated with mineralocorticoid antagonists: a one-year pilot study. Retina. 2016; 36:611–618.
28. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H. Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry. 2003; 60:24–28.
29. Chen J, Wang ZZ, Zhang S, Zuo W, Chen NH. Does mineralocorticoid receptor play a vital role in the development of depressive disorder? Life Sci. 2016; 152:76–81.
30. Tsai DC, Chen SJ, Huang CC, et al. Risk of central serous chorioretinopathy in adults prescribed oral corticosteroids: a population-based study in Taiwan. Retina. 2014; 34:1867–1874.
31. Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013; 33:1659–1672.
32. Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina. 2015; 35:1–9.